AEON

AEON Biopharma, Inc. Class A · AMEX

Sector Health Technology
Industry Pharmaceuticals: Major
Website aeonbiopharma.com
Employees(FY) 8
ISIN US00791X1000

Performance

-18.3%

-50.0%

-23.83%

-52.83%

-89.58%

YTD

-83.41%

Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.

Advanced Technical Analysis

Technical Analysis of AEON 2024-11-08

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 3 indicating strong downward momentum, an Oscillators Score of 43 suggesting a neutral stance, and a Technical Score of 23 reinforcing the bearish outlook. This combination signals caution for potential investors, as the prevailing trend appears to be negative.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of AEON

Stock Rank

Recent News & Updates

2024-09-29 20:00
AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting(Globenewswire)
2024-08-20 21:55
AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now(Yahoo Finance)
2024-08-19 04:05
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024(Globenewswire)
2024-08-12 04:05
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-07-08 20:00
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450(Globenewswire)
2024-05-28 21:35
Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround(Yahoo Finance)
2024-05-28 20:00
AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan(Globenewswire)
2024-05-14 04:05
AEON Biopharma Reports First Quarter 2024 Financial Results(Globenewswire)
2024-05-08 21:35
AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner(Yahoo Finance)
2024-05-08 20:00
AEON Biopharma Provides Update on Development Pipeline(Globenewswire)
2024-05-03 04:08
US Equity Markets Close Higher Friday Following Weak Jobs Report(Yahoo Finance)
2024-05-03 03:55
Sector Update: Health Care Stocks Mixed Late Afternoon(Yahoo Finance)
2024-05-03 02:37
Top Midday Decliners(Yahoo Finance)
2024-05-02 21:05
Sector Update: Health Care Stocks Mixed Pre-Bell Friday(Yahoo Finance)
2024-05-02 20:31
AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial(Yahoo Finance)
2024-05-02 19:00
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine(Globenewswire)
2024-03-30 10:53
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants(Globenewswire)
2024-03-29 04:15
AEON Biopharma Announces Redemption of Public Warrants(Globenewswire)
2024-03-29 03:45
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results(Globenewswire)
2024-03-19 16:30
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine(GlobeNewswire)
2024-03-19 16:29
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements(GlobeNewswire)
2024-03-19 04:30
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine(Globenewswire)
2024-01-18 16:05
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference(GlobeNewswire)
2024-01-18 03:05
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference(Globenewswire)
2023-12-12 08:00
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine(GlobeNewswire)
2023-12-11 19:00
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine(Globenewswire)
2023-11-14 15:49
AEON Biopharma Inc Reports Q3 2023 Financial Results Amid Clinical Advancements(Yahoo Finance)
2023-11-12 19:15
AEON Biopharma Reports Third Quarter 2023 Financial Results(Globenewswire)
2023-10-19 04:05
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine(Globenewswire)
2023-08-28 20:00
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®(Yahoo Finance)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.